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ABSTRACT 
URINARY PHTHALATE METABOLITE CONCENTRATIONS AND CANCER 
MORTALITY IN NHANES, 1999-2006 
MAY 2015 
AMY BRADSHAW KAISER, B.A., MOUNT HOLYOKE COLLEGE 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Katherine Reeves 
 
Four in ten people in the US will be diagnosed with cancer during their lifetime. 
Environmental exposures are important determinants of cancer risk, causing as many as 
19% of cancers worldwide.  Phthalates are a group of chemicals used to increase the 
flexibility of plastics and vinyl in household materials such as food packaging, plastic 
toys, wood finishes and adhesives.   Some phthalates may act as endocrine disruptors 
with hypothesized links to endometriosis, breast cancer, and reproductive outcomes. 
However, no research yet exists on phthalate exposure and all-cancer mortality. We 
investigated the relationship between seven urinary phthalate metabolites among 5,205 
adults in National Health and Nutrition Examination Survey (NHANES), from 1999 to 
2006 with mortality data through 2011. Urinary phthalate metabolites were measured in 
spot urine samples using HPLC-MS/MS and HPLC-ESI-MS/MS. Cox proportional 
hazard regressions were conducted to calculate hazard ratios and 95 percent confidence 
intervals for all-cancer mortality, stratified by gender. Mean creatinine adjusted 
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metabolite concentrations ranged from 0.03 – 3.86 ug/mg in males and 0.07 – 4.37 ug/mg 
in females. Age-adjusted and multivariate Cox proportional hazard models did not yield 
statistically significant results for any metabolites. Hazard ratios in the multivariate 
model for continuous, creatinine adjusted, log transformed metabolite concentrations, 
ranged from 0.90 to 1.27 in men and 0.86 to 1.07 in women. There was no evidence for a 
dose-response relationship in the quartile analyses, with p-values for trend above 0.12. 
This research contributes to the limited cancer literature on phthalate exposure that helps 
direct future regulations on plasticizers in consumer products.    
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CHAPTER 1 
INTRODUCTION 
In 2014, the rate of cancer in the US was 460.4 per 100,000 with an average 5-
year survival rate of 66.1 percent. Since 1992, the incidence and mortality rates of cancer 
have been slowly decreasing, but it is still one of the most burdensome diseases in the 
country. The three most common cancer sites are breast, lung, and colorectal, which 
together account for about 40 percent of all new cancer cases.1  Risk factors for cancer 
are extremely broad, and depend on the cancer site, and in some cases, the histological 
type. In general, they include lifestyle factors, such as smoking, diet, alcohol, and 
exercise; genetics; psychological stress; radiation and magnetic field exposure, including 
CT scans, x-rays, radon; infectious agents such as human immunodeficiency virus, 
Human papillomavirus,  and H. pylori; and chemical or environmental exposures, 
including asbestos, formaldehyde, some pesticides, and possibly bisphenol A and 
phthalates.2  
Phthalates are a family of chemicals ubiquitous in countless industrial products. 
They hold color and fragrance and add gloss to personal care products; provide time 
releasing for some pharmaceuticals; and most commonly, add flexibility to polyvinyl 
chloride (PVC).3 Higher molecular weight phthalates, including di-(2-ethylhexyl) 
phthalate (DEHP), di-isodecyl phthalate (DiBP), and di-isononyl pthalate (DiNP) are 
most common in construction material, clothing, children’s toys, household furnishings, 
and as a plasticizer in PVC.  Lower molecular weight phthalates, dibutyl phthalates 
(DBP), dimethyl phthalate (DMP), and diethyl phthalate (DEP), are typically used as 
solvents in adhesives, pharmaceuticals, waxes, inks, and cosmetics (Table 1).4, 5  
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Humans have opportunity to be exposed to phthalates through ingestion, 
inhalation, intravenous injection, and skin absorption. Phthalates are not covalently 
bound to the PVC plastics, and tend to leach, migrate or evaporate into the environment. 
3, 6  The most common route of exposure is ingestion (through food, medicine, or 
children’s toys), inhalation (house dust and indoor air), intravenous (medical tubing), and 
dermal absorption (direct contact with clothing, waxes, cleaning products, cosmetics).5  
Medical devices are a particularly common source of exposure. Phthalates (particularly 
DEHP) are used as softeners for medical tubing or medical bags used for administering 
blood and nutritional formulas, as well as gases for respiratory treatments, and are in 
medicine packaging and coatings of supplements and herbal treatments. Therefore, 
individuals undergoing medical treatment have phthalate exposure associated with each 
treatment (e.g. intravenous exposure to DEHP from a blood transfusion in a trauma 
patient is about 8.5 mg/kg/day)5.  
Phthalates are quickly metabolized in the body into monoesters, and then 
depending on the phthalate, further metabolized into oxidative products of their lipophilic 
aliphatic side chain, then excreted in urine and feces3.  According to the National Health 
and Nutrition Examination Survey (NHANES), several phthalate metabolites are 
detectable in the urine of 97 percent of the total US population,7 and adult women have 
particularly high levels of metabolites associated with phthalates used in cosmetics and 
personal care products.8  Phthalates are suspected to act as endocrine disruptors in 
humans, which may be associated with infertility, endometriosis, and some endocrine 
related cancers, possibly by mimicking naturally occurring hormones, blocking 
endogenous hormones from binding, or altering the production of hormones in the body.9 
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The National Toxicology Project has classified one phthalate DEHP as Group 2B, 
possibly carcinogenic to humans, based on sufficient evidence for carcinogenicity in 
animal studies. 10 
Physiology of PhthalateCancer Relationship 
The carcinogenic mechanism for phthalates is unclear and the specific 
carcinogenic mechanism and metabolism of endocrine disruptors is poorly understood. 
Endocrine disrupters are typically considered compounds that bind to steroid hormone 
receptors to mimic or block the transcriptional activation elicited by naturally circulating 
steroid hormones. Hsieh et al. demonstrated that phthalates could induce proliferation, 
migration, invasion, and tumor formation and initiate a cascade of events that facilitates 
cancer, specifically ER-negative breast cancer.11  
They can also act as hormone sensitizers by inhibiting histone deacetylase activity 
and can stimulate mitogen-activated protein kinase activity. Additionally, they may have 
effects on receptors other than ER, AR, and thyroid hormone receptor and can have 
genome-wide effects on DNA methylation.12 
Epidemiology of PhthalateCancer Relationship 
The association between phthalate exposure and all cancer mortality has not been 
previously been studied. However, three studies have examined breast cancer and 
exposures to phthalates or endocrine disruptors, and one study examined lung cancer and 
occupational exposures, including phthalates.  
 Two occupational case-control studies evaluated breast cancer. Aschengrau et al. 
13  evaluated occupational exposure to 18 estrogenic chemicals assigned according to job 
description, and risk of breast cancer among 261 employees compared to 753 population 
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controls. Cases only exposed to butylbenzyl phthalate (BBzP) (n=4 cases) had an 
adjusted odds ratio of 0.9 (95% CI: 0.3-2.9) compared to controls with the same 
exposure. Combined exposure to BBzP phthalate and other xenoestrogens (defined as any 
of 33 substances with estrogenic properties in E-SCREEN bioassay), had an adjusted OR 
of 0.7 (95% CI: 0.4-1.2) compared to controls with the same exposure. Brophy et al. 2012 
14 conducted compared occupational work history of 1,005 breast cancer cases with 1,146 
community controls. They reported that women in jobs with high exposures to endocrine 
disruptors had elevated breast cancer risk (OR=1.42, 95% CI: 1.18-1.73), with 
particularly elevated risks among automotive plastics manufacturing (OR=2.68, 95% CI: 
1.47-4.88).  
A third occupational case-control study15 compared 43 cases that died of lung 
cancer from 1976 to 1979 to community controls that died in the same time period. Cases 
were more likely to work in a plant that produced phthalates (OR=5.2), but the plant also 
produced large levels of soot. The analysis adjusted for age and smoking, but not soot 
exposures.     
These studies are limited by misclassification of exposure and lack of individual 
exposure. Since exposure assessment was based on work history, it is not clear exactly 
which chemicals are responsible for the increased risk. Especially in cases where 
participants held multiple jobs over a lifetime, results could be confounded by other 
occupational exposures. Records-based occupational studies also may not have 
comprehensive, reliable covariate data which introduces unadjusted confounding or 
residual confounding.  There could also be recall bias, typical of case-control studies, or 
chance findings.  
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Lopez Carrillo et al.16 conducted a case-control study of breast cancer, with 233 
cases and 221 age-matched controls, and assessed phthalate exposure through urine 
metabolites. For the sum of all metabolites, the authors reported slightly increased odds 
of breast cancer in the third tertile compared to the first tertile, which was not statistically 
significant (OR=1.09, 95% CI=0.69-1.71).  They also reported statistically significant 
increased odds of breast cancer in the third tertile compared to the first tertile in some 
metabolites: DEP metabolites, OR=2.20, 95% CI=1.33-3.63; DEHP metabolites, 
OR=1.68, 95% CI=1.01-2.78. However, they also found statistically significant 
protective effects when comparing the third tertile to the first:  BBzP metabolites, 
OR=0.46, 95% CI=0.27-0.79; DOP metabolites, OR=0.44, 95% CI: 0.24-0.80. These 
results demonstrate the importance of assessing individual compounds, since each 
phthalate does not affect risks of breast cancer equally; this study found that most either 
have no effect or a protective effect on risk. Additionally, the effect sizes in this study 
may be overestimated because phthalates are found in medical equipment and 
medications. Therefore, cases will have higher exposure to phthalates than controls due to 
their cancer treatments, not because their exposure increased their risk of cancer.  
Summary of Significance and Innovation 
Given the high percentage of Americans exposed to phthalates on a daily basis, 
further research on the health implications of these substances is increasingly important. 
The existing literature suggests possible health implications of phthalates and the possible 
carcinogenicity of endocrine disruptors. However, cancer incidence or mortality has not 
been adequately assessed. This study is significant given the prevalence of phthalates in 
consumer products, and its suspected carcinogenicity and is innovative by evaluating the 
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association between urinary phthalate metabolites and cancer mortality in a large 
population with a verified exposure assessment. 
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CHAPTER 2 
METHODS 
Study Design 
 Using a prospective cohort design, we conducted a mortality analysis to assess the 
association between urinary phthalate metabolites and all cancer mortality using four 
National Health and Nutrition Examination Survey (NHANES) series from 1999-2006, 
linked with mortality data through 2011. NHANES is a national survey from the National 
Center for Health Statistics, part of the Center for Disease Control and Prevention (CDC). 
The assessment included an interview component to collect sociodemographic, household 
and medical information; as well as a mobile examination component (MEC) for blood 
and urine samples which was conducted for a random sample of one third of the 
participants. The NHANES interview team included physicians, medical technicians and 
health interviewers. The interviews were conducted in the participants’ houses, and the 
MECs were conducted in mobile centers.17  
Study Population 
The NHANES survey is the longest ongoing survey of the US population. The 
survey began in the 1960s, with the continuous series beginning in 1999. Each NHANES 
series includes 2 years and enrolls about 10,000 participants each series. Participants are 
randomly selected through a complex survey design, designed to be representative of 
civilian, noninstitutionalized US population; African Americans, Mexican Americans, 
infants, children, and the elderly were oversampled to ensure the sample was fully 
representative. 17 The public-use linked mortality files provide linkage with the National 
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Death Index (NDI) and Social Security Administration (SSA) databases for vital status 
and cause of death data. Mortality data are available through December 31, 2011.18  
NHANES surveyed about 41,400 participants over the four series. Participants 
were eligible for our study if they were adults (more than 20 years old) who underwent 
the MEC assessment and were randomly selected for the phthalate assessment of the 
MEC assessment (n=5205, evenly distributed between each series)1. We further excluded 
participants who died within 12 months of the MEC assessment (n=67), who were ever 
diagnosed with a cancer other than melanoma (n=434), or who were pregnant at time of 
MEC assessment (n=378), to eliminate confounding by prevalent cancers or conditions, 
increased medicalization or changes in phthalate metabolism. We also excluded 
participants who had incomplete mortality follow-up (n=8). Our final study population 
included 5,205 participants (Table 2).  
Urinary Phthalate Metabolite Assessment  
Phthalate metabolites were measured on a random one-third sample of the MEC 
assessment participants, starting in 1999. One spot urine sample was collected from each 
participant, stored at -20°C and then shipped to Division of Environmental Health 
Laboratory Sciences, National Center for Environmental Health, Centers for Disease 
Control and Prevention for analysis.  We included include metabolites that were assessed 
for at least three NHANES series from 1999 to 2006, and that had more than 60 percent 
of samples above the level of detection: MBzP, MnBP, MEHP, MEP were measured 
starting in 1999 and are associated with BzBP, DBP, DEHP and DEP, respectively; 
                                                 
1 About 18,850 of the surveyed participants had missing follow-up data. However, 15,162 
of these were also missing phthalate data and 1,202 of them were less than 20 years old. 
Therefore, only 8 were eligible for our study, and later excluded.  
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MiBP, MCPP, MEHHP, MEOHP and were measured starting in 2001 and are associated 
with DBP, DnOP, DEHP, and DEHP, respectively.  In the 1999-2000 series, the MnBP 
and MiBP metabolites were not differentiated, so these measurements were combined in 
subsequent series for consistency.  Samples below the LOD were assigned the value of 
the LOD divided by the square root of two by the laboratory conducting the analyses.  
Each value was natural log transformed, and adjusted for urine dilution by dividing by 
creatinine concentration.   
Validation of Urinary Phthalate Metabolite Assessment  
Due to decisions made by NHANES, two different methods were used to assess 
phthalate concentration. From 1999 to 2002, urine was analyzed using high-pressure, 
liquid chromatography tandem mass spectrometry (HPLC-MS/MS). From 2003 to 2006, 
phthalate metabolites were analyzed using high performance liquid chromatography-
electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS/MS).   The precision 
of this method was evaluated by repeated measures of quality control pools over time and 
CVs were provided (Table 1).19-22 Urinary creatinine was also measured in each 
participant and used to adjust for urinary dilution.  
Cancer Mortality Assessment 
  NHANES participants were linked with mortality data through December 31, 
2011 by the National Center for Health Statistics (NCHS). Participants were matched to 
death certificates, National Death Index (NDI) records, SSA records, and Centers for 
Medicare and Medicaid Services, and then cause of death data was ascertained from the 
NDI and death certificates. Matches were determined using 12 matching variables and a 
probabilistic algorithm.18 Cause of death was recoded into 10 general categories for this 
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dataset. The code “002”, any malignant neoplasm, was used for this analysis.  Although 
we do not have site-specific cancer data, based on previous mortality data available 
through 2010, the most common cancers contributing to mortality were trachea, bronchus 
and lung cancer; colon, rectum and anus cancer; and non-Hodgkin’s lymphoma.  
To take advantage of data available in NHANES, we used cancer mortality as a 
proxy for cancer incidence. However, cancer mortality does not adequately capture 
survivable cancers which will be missed in this analysis, while aggressive cancers will be 
over-represented.  
Validation of Cancer Mortality 
The National Center for Health Statistics (NCHS) completed a calibration study 
to verify their linkage methodology for mortality follow-up.23  They used the NHANES I 
Epidemiologic Follow-up survey (conducted from 1971 to 1992), which includes 
participants for whom vital status was known. A sample was submitted to the NDI for 
match searches, and matches were compared with each other.  Of the decedents, 96.1 
percent were correctly classified as deceased and correctly matched with a death 
certificate. Among non-decedents, 99.4 percent were correctly classified as alive. In total, 
98.5 percent of NHEFS respondents were correctly classified.    
The NDI has documented cause of death data since 1979, and is the accepted 
source for mortality data for large studies. A validation study of the NDI cause of death 
data compared NDI underlying cause of death to the cause of death assigned by two 
nosologists. They provided discrepancy rates using the NCHS code as the reference. The 
discrepancy rate for all causes of death combined was four percent for NDI Plus codes 
and six percent to seven percent for the study nosologists' original codes. The 
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discrepancy rate for specific cancer sites was one percent for NDI Plus codes and three 
percent for the final study codes.24  Cancer mortality was assessed as a dichotomous 
variable. 
Covariate Assessment 
 We considered as possible covariates demographic, lifestyle, and health factors 
available from data obtained during the demographic or household section of the 
NHANES questionnaire. Age at home visit, family poverty-income ratio (PIR), BMI, and 
age at menarche, were assessed as continuous variables. Categorical variables included: 
race (Mexican American, other Hispanic, Non-hispanic White, Non-hispanic Black, other 
race/multi-race), gender (male, female), education (less than high school, high school 
graduate or GED, some college or AA degree, college graduate or above), country of 
birth (born in the US, born in Mexico, or born elsewhere), and marital status 
(married/living with partner, never married, widowed/divorced/separated), smoking 
status (smoker, non-smoker), menopausal status (pre- or post- menopausal), alcohol 
intake (none, light, moderate, heavy). 
Smoking status (dichotomous) was ascertained using the question “smoked at 
least 100 cigarettes in lifetime?” to reduce missing data. For the last 2 series, subjects 
were considered postmenopausal if the answer to the question “what is the reason that 
you have not had regular periods in past 12 months?” was “menopause/hysterectomy.” 
For the first 2 series they were considered postmenopausal if their answer this question 
was “going-gone through menopause or their answer to “have you had a hysterectomy?” 
was yes.   Alcohol intake was coded as light for 1-2 drinks per day, moderate for 3-4 
drinks per day, and heavy for more than 4 drinks per day. These were been identified 
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based existing literature on risk factors for cancer mortality and possible association with 
phthalate exposure (Table 2).  
Data Analysis  
Each phthalate metabolite was standardized by urinary creatinine levels to 
account for urinary dilution, and natural log transformed.   We calculated Pearson 
correlation coefficients were calculated for continuous variables and anova for 
categorical variables to assess crude correlations between each phthalate metabolite and 
covariates.  
Multivariable Cox proportional hazards regression was used to model the 
association between urinary creatinine-adjusted phthalate metabolite concentrations 
(continuously and in quartiles) and cancer mortality. Person-time was measured in 
months starting from MEC exam. Participants were right censored at of time of death 
from non-cancer cause or administrative censoring in December 2011.  
Two models were considered for each metabolite, each stratified by sex: model 1 
was adjusted for age, and model 2 was a multivariate analysis adjusted for age, BMI, 
PIR, race, smoking, education, country of birth, marital status and alcohol intake. In the 
female strata, model 2 was also adjusted for menopausal status and parity.  Risk factors 
for cancer are abundant, and vary greatly between cancer sites. When choosing 
covariates, we took into account common risk factors for most prevalent cancers (cancers 
of the colon, breast and lung),2 literature on phthalates, and results from our bivariate 
analyses. 
For all statistical analyses, SAS 9.3 was used.  
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CHAPTER 3 
RESULTS 
Our study population was approximately 51% male and 49% female. The average 
age at entry was 48 years for men and 50 years for women and about 49% were non-
Hispanic White, 22% were Mexican American, and 20% were Black. About 30% had 
less than a high school education, and 20% of men were college graduates for more, 
while 17% of women were college graduates. Among women, 65% were post-
menopausal (Table 3). Mortality follow-up yielded 132 cancer deaths, 81 among men and 
51 among women (Table 4). 
Metabolites MBzP, MEHP, and MEP were measured in 2,654 males and 2,511 
females; metabolites MCPP, MEHHP, MEOHP and MnBP were measured in 2,042 
males and 1,896 females.  In general, women had higher concentrations than men, with 
the biggest difference in mean for MEP (males: 3.86 ug/mg, females: 4.37 ug/mg). Males 
had a slightly higher mean concentration of MBzP, but larger standard deviation (SD) 
(males: 0.17 ug/mg, SD: 2.14; females: 0.15 ug/mg; SD:  0.25 ug/mg) (Table 5).  
Bivariate analyses showed that age was statistically significantly associated with 
most phthalate metabolites for men and women.  Race was significantly associated with 
MEHP, MnBP, MEHHP, MEOHP, and MCPP in men, and with MBZP, MnBP and 
MCPP in women, with Hispanics having the highest levels overall. Participants who were 
never married had higher concentrations than married or divorced/widowed participants, 
and marital status was associated with every metabolite except MEHP and MEOHP in 
men, and MEHP and MnBP in women. Among women, parity was not associated with 
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any metabolite, while premenopausal women had overall higher concentrations (Table 6, 
6a, 7, 7a).  
Due to missing data, Cox proportional hazard regressions in men included 2,359 
subjects and 59 events for MEHP, MBZP and MnBP, and 1,886 participants and 43 
events for MEHHP, MEOHP, and MCPP; and 2358 participants and 59 events for MEP. 
Results of the age-adjusted analysis of continuous metabolites were mostly null with 
hazard ratios ranging from 0.87 to 1.29. The multivariate analysis of continuous 
metabolites, adjusted for age, BMI, PIR, race, smoking, education, place of birth, marital 
status, and alcohol intake, yielded hazard ratios ranging from 0.90 to 1.26, with 
confidence intervals including 1. The quartile analysis yielded similar results, with p-
values for trend much large than 0.05, with the exception of MEP, which had reducing 
risk estimates with higher exposure, and a p-value of 0.06.  
In women, Cox proportional hazard regressions results included 2,025 subjects 
and 38 events for MEHP, MBZP and MnBP; 1,576 participants and 26 events for 
MEHHP, MEOHP, and MCPP; and 2,022 participants and 37 events for MEP.  Results of 
the age-adjusted and multivariate analyses of continuous metabolites were mostly null 
with hazard ratios ranging from 0.86 to 1.07. Some quartile analyses were suggestive of 
increased risks with exposure, but the trends were not approaching significance (lowest 
p-trend=0.12).  
Results for a fully adjusted Cox proportional hazard regression for men and 
women combined did not yield meaningfully different results (not shown).  
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CHAPTER 4 
DISCUSSION 
We found no evidence of an association between urinary phthalate metabolites 
and all-cancer mortality. Results for multivariate Cox proportional hazard regressions 
were null, as were analysis of exposure in quartiles. As expected, we observed 
differences in exposure between men and women, races and age, and between individual 
phthalates.  
Overall, previous literature is limited to case-control studies from occupational 
settings that lack individual exposure assessment or exposure to specific compounds. The 
single study that does have results for individual compounds, Lopez Carillo et al.16 
reported increased odds of breast cancer for DEP metabolites (MEP) and DEHP 
metabolites (MEHP, MEHHP, MEOHP) protective effects for BzBP metabolites (MBzP) 
and DnOP metabolites (MCPP).  We were unable to reproduce these results, and found 
that in men, MBzP actually had the highest hazard ratio.  
This study has several strengths. We used a cohort design with individual 
exposure assessment and specific phthalate compounds with mortality follow-up to 
conduct a time-to-event analysis which allowed us to take into account person-time for 
the entire cohort. Our data for exposure, outcome and covariates was reliable, and 
residual confounding is unlikely due to measurement error.   One possible exception is 
confounding due to unmeasured medication use.  We were unable to account for 
medication use in our analyses, which could increase phthalate metabolite levels. 7 To 
reduce the chances of including very ill individuals in our analysis, we excluded 
participants who died within 1 year of baseline.  Lastly, NHANES is a random selection 
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of the U.S. population, so selection bias in the overall dataset was unlikely and our results 
could be are broadly generalizable.   
Our study had several limitations.  First, we used cancer mortality as a proxy for 
cancer incidence; however, many cancers are survivable: overall, cancers have an on 
average a 61.1 percent 5-year survival rate, 25 while many of the most prevalent cancers 
have even higher rates. Therefore, many incident cancer cases likely went undetected in 
our analysis because participants either survived or survived past end of follow-up.  
Additionally, we could not assess site-specific cancer mortality, and missed the 
opportunity to analyze cancers likely to be associated with phthalate exposure (hormone-
related cancers).  
Secondly, phthalate exposure was assessed through spot urine samples, collected 
at different times of the day for each participant. Phthalates are quickly metabolized in 
the body, so a single urine sample will only reflect recent (<1 day) exposures.   We are 
unsure if a single urine sample is representative of a participant’s current actual phthalate 
exposure, and what the likelihood is that that sample can represent longer term phthalate 
exposures.  In study among men of reproductive age, the day-to-day variance ranged 
from 27.2% to 58.1%, 30-day cycle variances ranged from 1.5% to 16.3%, so the authors 
concluded that day-to-day variance accounts for most of the variance within 30 days. 26 
There is substantial variance in phthalate exposure that will not be captured by a single 
urine sample and limits the ability of our samples to adequately estimate true exposures.  
 The authors also assessed the predictability of a single spot urine sample in 
relation to 3-month average in tertiles. They reported sensitivities of 0.56 (MEHP), 0.63 
(MBzP), 0.63 (MEP), and 0.67 (MBP).26  These are very modest sensitivities, and 
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suggest that only 55-70 percent of samples were correctly classified into tertiles, so our 
quartile analyses only slightly increase the accuracy of the exposure assessment. 
 Misclassification of exposure is likely, especially if each sample is intended to 
estimate long-term exposures.  This is a moderate non-differential misclassification of 
exposure that will affect subjects regardless of outcome and bias the results toward the 
null. In general, ability of a spot sample to predict average exposure varies by metabolite; 
MEP and MBP are more representative, while MEHP, MEHHP, DEHP, are less 
representative. 26, 27 
Additional misclassification of exposure may persist due to urine concentration, 
despite adjusting for creatinine. Creatinine adjustment is not appropriate for compounds 
secreted through tubular secretion, which is suggested to be the case for phthalates, and 
creatinine varies by factors such as age, BMI, exercise, and diet. Alternative methods 
used are specific gravity and urinary osmolality. 26, 27  However, creatinine is what is 
recommended in the NHANES dataset.     
Another related concern is the temporal relationship between exposure and 
cancer. Our study had between 5 and 11 years of follow-up on each participant. Since 
cancers tend to have long latency periods, it is likely that a longer follow-up period would 
capture more events. Additionally, we also did not take into account periods of 
sensitivity; exposure in utero, during puberty or during childhood which could have a 
larger effect on risk of cancer than exposure in other times of life. Lastly, this analysis is 
likely underpowered to detect effects. The sample size was small after exclusions, and 
events were lost in the regressions due to missing data in covariates.  
 
  
18 
 
CHAPTER 5 
CONCLUSION 
 We did not observe associations between all-cancer mortality and phthalate 
metabolites (MBzP, MCPP, MEHHP, MEHP, MEOHP, MEP, MnBP) in age-adjusted or 
multivariate Cox proportional hazard regressions, stratified by gender. Our study was 
limited by power, mortality data instead of cancer incidence data, and misclassification of 
exposure.  However, it contributed longitudinal data with individual exposure assessment 
to the existing literature on potential carcinogenicity of phthalates. Our study was 
inconclusive, and warrants additional epidemiological, as well as toxicological, research 
on the subject. We were unable to assess site-specific cancers, which would be essential 
for further research. We also do not know how much our results were affected by 
confounding due to exposure to medical devices or if our exposure assessment was 
adequately precise. It is also possible that our study missed the window of sensitivity for 
this exposure-outcome mechanism. Given the high percentage of Americans exposed to 
phthalates on a daily basis, further research on the health implications of these substances 
is increasingly important.   
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Table 1: Sources of exposure, metabolites and analytical data for assessed phthalates    
Parent 
Compound 
Sources of Exposurea Metabolite Series 
CV (99-
00)b 
CV (01-
02)c 
CV (03-
04)d 
CV (05-06)e 
 Benzylbutyl 
phthalate (BzBP) 
Floorings, paints, carpet backings, 
adhesives, wood finishers, wallpaper, 
PVC products  
Mono-benzyl Phthalate 
(MBzP) 
1999-
2006 
9.6-12.8% 5.4-14.2% 6.3-6.4% 6.8-8.9% 
Di-butyl phthalate 
(DBP)  
Deodorants, perfumes, personal care 
products, aftershave, cosmetics, 
pharmaceutical/herbal coating, 
chemiluminescent glow sticks  
Mono-n-butyl Phthalate 
(MnBP) 
1999-
2006 
7.2-22.1% 4.0-17.2% 7-7.4% 7.5-17.4% 
Mono-isobutyl Phthalate 
(MiBP) 
2001-
2006 
  7.2-8.3% 5.8-8.6% 7.3-13.2% 
Di 2-ethylhexyl 
phthalate (DEHP) 
PVC containing medical tubing, medical 
devices, food packaging, indoor air, 
plastic toys, tablecloths, floor tiles, 
furniture upholstery, shower curtains, 
garden hoses, rainwear, baby pants, dolls, 
shoes, automobile upholstery and tops, 
and sheathing for wire and cable 
Mono-(2-ethyl)-hexyl Phthalate 
(MEHP) 
1999-
2006 
10.5%-
18.2% 
8.6-15.8% 7.6-10.5% 6.3-12.0% 
Mono-(2-ethyl-5-
hydroxyhexyl) Phthalate 
(MEHHP) 
2001-
2006 
 8.6-15.8% 6.7-8.4% 3.8-5.7% 
Mono-(2-ethyl-5-oxohexyl) 
Phthalate (MEOHP) 
2001-
2006 
  4.8-6.0% 6.6-9.6% 3.3-4.4% 
Diethyl phthalate 
(DEP) 
Deoderants, perfumes, personal care 
products, aftershave, cosmetics, 
pharmaceutical/herbal coating, 
insecticide 
Mono-ethyl Phthalate (MEP) 
1999-
2006 
4.9-10.0% 4.7-10.6% 5.1-6.0% 2.9-5.2% 
 Di-n-octyl 
phthalate (DnOP) 
Medical tubing and blood storage bags, 
wire and cables, carpetback coating, floor 
tile, and adhesives, cosmetics and 
pesticides 
Mono-(3-carboxypropyl) 
phthalate (MCPP) 
2001-
2006 
  4.1-4.3% 
10.9-
12.3% 
14.0-15.5% 
a Adapted from: Sathyanarayana S. Phthalates and Children's Health. Curr Probl Pediatr Adolesc Health Care 2008;34 49. 
b CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 1999-2000. 
http://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/PHPYPA_met_phthalates.pdf . 2010. 3-29-2015.  
c CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2001-2002. 
http://www.cdc.gov/nchs/data/nhanes/nhanes_01_02/PHPYPA_b_met_phthalates.pdf . 2010. 3-29-2015.  
d CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2003-2004. 
 http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/l24ph_c_met.pdf.  2013. 3-29-2015.  
e CDC/National Center for Environmental Health. Laboratory Procedure Manual, Phthalate Monoesters in Urine, NHANES 2005-2006.  
http://www.cdc.gov/nchs/data/nhanes/nhanes_05_06/PHTHTE_D_met.pdf.  2013. 3-29-2015.  
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Table 2: Number and percent in final study sample, NHANES 1999-2006 
Original Study Sample (adults eligible for follow up and 
phthalate data) 6059 % 
Incomplete follow up 8 0.1% 
Died within 12 months of baseline 67 1.1% 
Ever diagnosed with cancer (except non-melanoma skin) 434 7.2% 
Pregnant at time of MEC 378 6.2% 
Final Sample Size 5205 86% 
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Table 3: Distribution of covariates, NHANES 1999-2006 
  Males (n=2669; 51%) Females (n=2536, 49%) 
  M  SD missing M SD missing 
Age (years) 48.61 17.7 0 50.05 18.1 0 
BMI (kg/m2) 28.16 5.7 56 28.85 7.1 44 
Ratio of family income to poverty  2.73 1.6 181 2.62 1.6 209 
  N   % missing N   % missing 
Race   0   0 
   Mexican American 595 22.3  563 22.2  
   Other hispanic 115 4.3  113 4.5  
   Non-Hispanic White 1327 49.7  1221 48.2  
   Non-Hispanic Black 545 20.4  546 21.5  
   Other Race /multi-race 87 3.3   93 3.7   
Smoking   1   3 
   Smoked > 100 cigarettes in 
lifetime 
1518 56.9  976 38.5  
   Smoked< 100 cigarettes in 
lifetime 
1150 43.1   1557 61.5   
Education level   5   4 
   Less than high school 840 31.5  777 30.7  
   High school grad/GED or 
Equivalent 
626 23.5  581 23.0  
   Some college or AA degree 665 25.0  727 28.7  
   College Graduate or above 533 20.0   447 17.7   
Born in US or abroad   2   2 
   Born in US 2001 75.0  1986 78.4  
   Born in Mexico 382 14.3  324 12.8  
   Born elsewhere 284 10.7   224 8.8   
Marital status   67   61 
   Married /living with partner 1764 67.8  1384 55.9  
   Never married 448 17.2  351 14.2  
   Widowed, divorced, separated 390 15.0   740 29.9   
Menopausal status      102 
   Premenopausal --- --- --- 1192 49.0  
   Post menopausal --- --- --- 1242 51.0   
Parity      352 
   Nulliparous --- --- --- 255 11.7  
   1 live birth --- --- --- 327 15.0  
    More than 1 live birth --- --- --- 1602 73.4   
Alcohol intake   0   0 
   None 337 12.6  780 30.8  
   Light (1-2 drinks/day) 1435 53.8  1420 56.0  
   Moderate (3-4 drinks/day) 457 17.1  237 9.4  
   Heavy (>4 drinks/day) 440 16.5   99 3.9   
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Table 4: Distribution of cancer mortality, NHANES 1999-2006 with 
follow-up through 2011 
  All Males Females 
Cancer mortality 
132 81 (61%) 51  (39%) 
 
 
 
Table 5: Distribution of creatinine adjusted, phthalate metabolite 
concentration (ug/mg), NHANES 1999-2006 
  Males Females 
  Mean SD N Mean SD N 
MBzP 0.17 2.14 2654 0.15 0.25 2511 
MCPP 0.03 0.10 2042 0.04 0.15 1896 
MEHHP 0.41 1.01 2042 0.45 1.13 1896 
MEHP 0.07 0.21 2654 0.07 0.24 2511 
MEOHP 0.25 0.60 2042 0.29 0.69 1896 
MEP 3.86 10.29 2653 4.37 17.95 2507 
MnBP 0.35 3.23 2042 0.43 1.55 1896 
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Table 6: Distribution of creatinine adjusted, log transformed phthalate metabolite concentration (ug/mg) and 
coefficients, males, NHANES 1999-2006 
  MEHP MEP MBzP MnBP MEHHP MEOPH MCPP 
 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Age (years) -0.13 (<.01) 0.02 (0.32) 
-0.04 
(0.04) 
0.05(0.04) -0.05(0.03) -0.02(0.32) 0.11(<.001) 
Body Mass Index 
(kg/m2) 
-0.02 (0.33) 0.05(0.02) 0.01 (0.62) -0.02(0.28) 0.07 (<0.01) 0.07(<0.00) 0.01(0.66) 
Family PIR 0.03 (0.17) -0.03(0.15) 
-0.12 
(<0.01) 
-0.12(<0.01) 0.07 (<0.01) 0.08(<0.01) 0.00(0.83) 
  MEHP MEP MBzP MnBP MEHHP MEOHP MCPP 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Race        
   Mexican 
American 
0.03 (3.22) 1.40 (4.22) 0.06 (2.69) 0.19 (2.23) 0.15 (2.97) 0.10 (2.8) 0.02 (2.34) 
   Other hispanic 0.04 (3.9) 1.60 (4.35) 0.08 (2.64) 0.21 (1.9) 0.20 (3.00) 0.12 (2.86) 0.02 (2.34) 
   Non-Hispanic 
White 
0.03 (3.35) 0.98 (4.39) 0.07 (2.77) 0.18 (2.25) 0.18 (3.22) 0.12 (3.10) 0.02 (2.39) 
   Non-Hispanic 
Black 
0.03 (3.67) 1.48 (4.06) 0.07 (2.77) 0.19 (2.20) 0.17 (3.22) 0.11 (3.06) 0.01 (2.56) 
   Other Race 
/multi-race 
0.02 (2.89) 0.72 (3.82) 0.06 (2.97) 0.21 (2.89) 0.14 (2.92) 0.08 (2.80) 0.01 (2.53) 
ANOVA p-value 0.01 0.08 <0.01 0.12 0.01 0.01 <0.01 
Smoking        
   Smoker 0.03 (3.39) 1.21 (4.62) 0.07 (2.80) 0.18 (2.32) 0.17 (3.22) 0.11 (3.10) 0.02 (2.51) 
   Non-smoker 0.03 (3.42) 1.12 (3.94) 0.07 (2.69) 0.17 (2.14) 0.18 (3.03) 0.11 (2.92) 0.02 (2.32) 
ANOVA p-value 0.50 0.09 0.20 <0.01 0.13 0.15 0.07 
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Table 6a: Distribution of creatinine adjusted, log transformed phthalate metabolite concentration (ug/mg) and coefficients, 
males, NHANES 1999-2006, continued 
  MEHP MEP MBzP MnBP MEHHP MEOHP MCPP 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Education level        
   Less than high school 0.02 (3.13) 1.32 (4.66) 0.07 (2.89) 0.20 (2.29) 0.14 (2.92) 0.09 (2.80) 0.02 (2.44) 
   High school grad or 
equivalent 
0.02 (3.53) 1.25 (4.18) 0.07 (2.56) 0.18 (2.18) 0.18 (3.10) 0.11 (3.03) 0.02 (2.44) 
   Some college or AA  0.03 (3.67) 1.12 (4.18) 0.07 (2.75) 0.18 (2.25) 0.19 (3.25) 0.12 (3.10) 0.02 (2.51) 
   College graduate or above 0.03 (3.39) 0.95 (4.01) 0.06 (2.77) 0.17 (2.18) 0.19 (3.29) 0.12 (3.16) 0.02 (2.36) 
ANOVA p-value 0.03 <0.01 <0.01 <0.01 <0.01 <0.01 0.38 
Born in US or abroad        
   Born in US 0.03 (3.46) 1.11 (4.31) 0.07 (2.75) 0.18 (2.23) 0.18 (3.22) 0.11 (3.10) 0.02 (2.48) 
   Born in Mexico 0.03 (3.10) 1.54 (4.14) 0.06 (2.72) 0.19 (2.29) 0.15 (2.92) 0.09 (2.75) 0.02 (2.16) 
   Born elsewhere 0.03 (3.46) 1.2 (4.35) 0.06 (2.80) 0.23 (2.23) 0.16 (2.97) 0.1 (2.80) 0.02 (2.53) 
ANOVA p-value 0.10 <0.01 <0.01 <0.01 0.01 0.01 0.22 
Marital status        
   Married /living with 
partner 
0.03 (3.32) 1.17 (4.31) 0.06 (2.75) 0.18 (2.23) 0.17 (3.13) 0.11 (2.97) 0.02 (2.41) 
   Never married 0.03 (3.82) 1.08 (3.86) 0.07 (2.80) 0.18 (2.27) 0.18 (3.46) 0.11 (3.29) 0.02 (2.56) 
   Widowed, divorced, 
separated 
0.02 (3.29) 1.28 (4.9) 0.08 (2.69) 0.20 (2.29) 0.17 (2.94) 0.11 (2.92) 0.02 (2.39) 
ANOVA p-value 0.01 <0.01 0.24 0.11 0.98 0.97 <0.01 
Alcohol intake        
   None 0.02 (3.29) 1.19 (4.44) 0.07 (2.48) 0.18 (2.27) 0.15 (2.72) 0.1 0(2.61) 0.02 (2.51) 
   Light (1-2 drinks/day) 0.03 (3.35) 1.13 (4.39) 0.07 (2.80) 0.18 (2.23) 0.18 (3.03) 0.11 (2.92) 0.02 (2.39) 
   Moderate (3-4 drinks/day) 0.03 (3.67) 1.25 (3.97) 0.07 (2.48) 0.18 (2.16) 0.18 (3.6) 0.11 (3.46) 0.02 (2.39) 
   Heavy (>4 drinks/day) 0.03 (3.42) 1.21 (4.39) 0.07 (3.13) 0.19 (2.39) 0.17 (3.35) 0.10 (3.16) 0.02 (2.53) 
ANOVA p-value 0.79 0.14 0.53 0.99 0.11 0.19 0.01 
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Table 7: Distribution of creatinine adjusted, log transformed phthalate metabolite concentrations (ug/mg), females, NHANES 
1999-2006 
  MEHP MEP MBzP MnBP MEHHP MEOPH MCPP 
Pearson coefficient 
Coefficient 
(p-value) 
Coefficient (p-
value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Age (years) -0.09 (<0.01) -0.06 (0.01) -0.06 (0.01) 0.00 (0.85) -0.04 (0.13) -0.04 (0.07) 0.11 (<0.1) 
Body Mass Index 
(kg/m2) 
-0.08 (<0.01) 0.04 (0.11) 0.06 (0.01) -0.04 (0.13) 0.05 (0.04) 0.05 (0.02) -0.02 (0.40) 
Family PIR 0.02 (0.38) -0.04 (0.07) -0.16 (<0.01) -0.09 (<0.01) 0.04 (0.07) 0.05 (0.05) -0.02 (0.33) 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Race M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) 
   Mexican American 0.03 (2.97) 2.03 (3.35) 0.08 (2.77) 0.29 (2.29) 0.19 (2.69) 0.13 (2.56) 0.02 (2.41) 
   Other hispanic 0.03 (2.97) 2.2 (3.49) 0.1 (2.41) 0.39 (2.12) 0.25 (2.51) 0.16 (2.59) 0.03 (2.18) 
   Non-Hispanic White 0.03 (3.10) 1.26 (3.63) 0.09 (2.69) 0.26 (2.25) 0.21 (2.92) 0.14 (2.86) 0.02 (2.32) 
   Non-Hispanic Black 0.03 (3.13) 1.88 (3.56) 0.09 (2.69) 0.28 (2.16) 0.22 (2.94) 0.14 (2.89) 0.02 (2.41) 
   Other Race /multi-race 0.03 (3.10) 0.93 (4.39) 0.08 (2.97) 0.28 (2.27) 0.18 (3.06) 0.12 (2.86) 0.02 (2.89) 
   ANOVA p-value 0.82 0.06 <0.01 <0.01 0.11 0.37 <0.01 
Smoking        
   Smoker 0.03 (2.94) 1.54 (3.74) 0.09 (2.80) 0.29 (2.29) 0.20 (2.66) 0.13 (2.64) 0.02 (2.41) 
   Non-smoker 0.03 (3.13) 1.55 (3.6) 0.08 (2.66) 0.26 (2.2) 0.21 (3.00) 0.14 (2.89) 0.02 (2.39) 
   ANOVA p-value 0.12 <0.01 <0.01 0.6 0.51 0.15 0.59 
Menopausal status        
   Premenopausal 0.04 (3.29) 1.68 (3.67) 0.09 (2.61) 0.28 (2.23) 0.22 (3.13) 0.15 (3.03) 0.02 (2.39) 
   Postmenopausal 0.03 (2.86) 1.43 (3.63) 0.08 (2.77) 0.27 (2.25) 0.20 (2.64) 0.13 (2.59) 0.02 (2.41) 
   ANOVA p-value <0.01 0.10 0.79 0.01 0.01 <0.01 <0.01 
Parity        
   Nulliparous 0.03 (3.00) 1.45 (3.97) 0.07 (2.77) 0.26 (2.12) 0.24 (2.89) 0.16 (2.80) 0.02 (2.39) 
   1 live birth 0.03 (3.10) 1.77 (3.78) 0.08 (2.66) 0.28 (2.18) 0.21 (2.97) 0.14 (2.97) 0.02 (2.32) 
    More than 1 live birth 0.03 (3.06) 1.52 (3.56) 0.09 (2.72) 0.28 (2.29) 0.20 (2.86) 0.13 (2.75) 0.02 (2.41) 
   ANOVA p-value 0.55 0.15 0.35 0.17 0.16 0.08 0.21 
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Table 7a: Distribution of creatinine adjusted, log transformed phthalate metabolite concentrations (ug/mg), females, NHANES 
1999-2006, continued 
  MEHP MEP MBzP MnBP MEHHP MEOPH MCPP 
Pearson coefficient 
Coefficient (p-
value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Coefficient 
(p-value) 
Education level        
   Less than high school 0.03 (3.13) 1.72 (3.67) 0.09 (2.94) 0.28 (2.29) 0.19 (2.86) 0.13 (2.75) 0.02 (2.64) 
   High school grad or Equivalent 0.03 (3.00) 1.67 (3.56) 0.09 (2.53) 0.28 (2.20) 0.21 (2.83) 0.14 (2.77) 0.02 (2.25) 
   Some college or AA degree 0.03 (3.00) 1.49 (3.71) 0.09 (2.61) 0.26 (2.14) 0.20 (2.83) 0.13 (2.75) 0.02 (2.29) 
   College Graduate or above 0.03 (3.16) 1.22 (3.53) 0.07 (2.69) 0.27 (2.39) 0.23 (3.03) 0.15 (2.97) 0.02 (2.41) 
   ANOVA p-value 0.6 0.01 0.27 <0.01 0.02 0.07 0.65 
Born in US or abroad        
   Born in US 0.03 (3.29) 1.48 (3.63) 0.09 (2.72) 0.27 (2.23) 0.21 (2.89) 0.14 (2.83) 0.02 (2.39) 
   Born in Mexico 0.03 (3.03) 2.01 (3.25) 0.07 (2.80) 0.28 (2.27) 0.18 (2.92) 0.12 (2.69) 0.02 (2.44) 
   Born elsewhere 0.03 (3.10) 1.65 (4.26) 0.07 (2.46) 0.34 (2.27) 0.19 (2.61) 0.13 (2.56) 0.02 (2.34) 
   ANOVA p-value 0.34 <0.01 <0.01 <0.01 0.02 0.08 0.03 
Marital status        
   Married /living with partner 0.03 (3.13) 1.49 (3.67) 0.08 (2.75) 0.26 (2.29) 0.20 (2.97) 0.13 (2.92) 0.02 (2.36) 
   Never married 0.03 (3.16) 1.75 (3.32) 0.08 (2.86) 0.28 (2.25) 0.23 (2.92) 0.15 (2.80) 0.02 (2.34) 
   Widowed, divorced, separated 0.03 (2.92) 1.58 (3.74) 0.09 (2.59) 0.30 (2.12) 0.21 (2.64) 0.14 (2.59) 0.02 (2.48) 
   ANOVA p-value 0.09 0.02 <0.01 0.14 0.03 0.02 <0.01 
Alcohol intake        
   None 0.03 (3.00) 1.52 (3.39) 0.09 (2.69) 0.26 (2.20) 0.18 (2.72) 0.12 (2.64) 0.02 (2.36) 
   Light (1-2 drinks/day) 0.03 (3.06) 1.52 (3.82) 0.08 (2.72) 0.27 (2.29) 0.22 (2.92) 0.14 (2.86) 0.02 (2.36) 
   Moderate (3-4 drinks/day) 0.03 (3.22) 1.82 (3.42) 0.10 (2.66) 0.31 (1.93) 0.21 (2.92) 0.14 (2.83) 0.02 (2.53) 
   Heavy (>4 drinks/day) 0.03 (3.49) 1.54 (4.10) 0.13 (2.56) 0.38 (2.29) 0.26 (2.92) 0.18 (2.89) 0.02 (2.75) 
   ANOVA p-value 0.68 <0.01 0.17 0.01 <0.01 0.01 0.24 
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N Events HR 95% CI LB 95% CI UB HR 95% CI LB 95% CI UB
MEHP
Continuous 2359 59 0.99 0.78 1.24 0.97 0.77 1.23
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 1.33 0.69 2.56 1.29 0.67 2.51
3rd quartile 1.22 0.60 2.49 1.09 0.53 2.25
4th quartile 1.09 0.50 2.37 1.06 0.48 2.33
p-trend 0.79 0.92
MEP
Continuous 2358 59 0.91 0.77 1.08 0.89 0.75 1.06
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.70 0.35 1.40 0.64 0.32 1.30
3rd quartile 0.67 0.33 1.37 0.61 0.30 1.27
4th quartile 0.60 0.30 1.20 0.51 0.25 1.05
p-trend 0.13 0.06
MBzP
Continuous 2359 59 1.29 1.01 1.66 1.27 0.98 1.64
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 1.45 0.70 3.02 1.30 0.62 2.74
3rd quartile 2.16 1.07 4.38 2.23 1.09 4.55
4th quartile 1.25 0.56 2.80 1.13 0.50 2.55
p-trend 0.30 0.38
MnBP
Continuous 1886
c 43 1.08 0.74 1.58 1.07 0.73 1.56
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.98 0.45 2.14 0.98 0.44 2.17
3rd quartile 1.15 0.52 2.57 1.04 0.46 2.35
4th quartile 0.73 0.29 1.83 0.69 0.27 1.76
p-trend 0.66 0.54
MEHHP
Continuous 1886
c 43 0.90 0.68 1.19 0.92 0.70 1.21
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.90 0.44 1.86 0.97 0.46 2.03
3rd quartile 0.30 0.10 0.88 0.32 0.11 0.95
4th quartile 0.82 0.37 1.84 0.82 0.36 1.88
p-trend 0.21 0.23
MEOHP
Continuous 1886
c 43 0.87 0.64 1.17 0.89 0.67 1.20
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.94 0.45 1.96 1.05 0.50 2.22
3rd quartile 0.40 0.15 1.09 0.44 0.16 1.23
4th quartile 0.83 0.37 1.88 0.82 0.35 1.88
p-trend 0.29 0.31
MCPP
Continuous 1886c 43 0.94 0.67 1.32 0.92 0.66 1.30
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.54 0.22 1.33 0.56 0.22 1.42
3rd quartile 0.87 0.40 1.88 0.87 0.39 1.91
4th quartile 0.76 0.34 1.72 0.76 0.33 1.75
p-trend 0.70 0.72
a 
Age-adjusted Cox proportional hazard regression
CAssessed for 3 out of 4 series
Model 1
a
Model 2
b
Table 8. Adjusted hazard ratios and 95% confidence intervals for cancer mortality and creatinine adjusted, log 
transformed urinary phthalate metabolite concentration (ug/mg), males, NHANES 1999-2006
b
Cox proportional hazard regression, adjusted for age, BMI, ratio of family income to poverty, race, smoking, education, diabetes status, place of birth, 
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N Events HR 95% CI LB 95% CI UB HR 95% CI LB 95% CI UB
MEHP
Continuous 2025 38 0.94 0.69 1.27 0.98 0.72 1.34
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.86 0.38 1.94 0.94 0.41 2.17
3rd quartile 0.28 0.09 0.89 0.31 0.10 1.00
4th quartile 0.91 0.39 2.09 1.05 0.44 2.47
p-trend 0.42 0.63
MEP
Continuous 2022 37 1.06 0.83 1.35 1.07 0.84 1.37
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.53 0.20 1.39 0.53 0.20 1.41
3rd quartile 0.56 0.21 1.47 0.59 0.22 1.59
4th quartile 1.11 0.49 2.55 1.19 0.50 2.83
p-trend 0.66 0.54
MBzP
Continuous 2025 38 0.98 0.71 1.35 1.01 0.71 1.42
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.68 0.29 1.61 0.67 0.28 1.60
3rd quartile 0.32 0.11 0.90 0.32 0.11 0.92
4th quartile 0.76 0.34 1.70 0.82 0.36 1.88
p-trend 0.33 0.43
MnBP 1576
c 26
Continuous 0.86 0.53 1.38 0.92 0.56 1.50
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 1.91 0.49 7.39 2.07 0.53 8.10
3rd quartile 1.28 0.32 5.12 1.55 0.38 6.33
4th quartile 1.38 0.38 5.01 1.62 0.44 6.01
p-trend 0.95 0.73
MEHHP 1576
c 26
Continuous 0.95 0.63 1.42 0.94 0.62 1.42
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 1.15 0.41 3.23 1.15 0.40 3.29
3rd quartile 0.66 0.21 2.05 0.66 0.21 2.07
4th quartile 0.63 0.19 2.05 0.64 0.19 2.12
p-trend 0.27 0.29
MEOHP
Continuous 1576
c 26 0.87 0.56 1.34 0.86 0.56 1.33
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 1.70 0.59 4.89 1.60 0.54 4.77
3rd quartile 0.84 0.27 2.63 0.84 0.26 2.70
4th quartile 0.45 0.11 1.88 0.42 0.10 1.80
p-trend 0.12 0.12
MCPP 1576
c 26
Continuous 0.91 0.56 1.45 0.90 0.55 1.49
1st quartile (referent) 1.00 ---- ---- 1.00 ---- ----
2nd quartile 0.29 0.06 1.50 0.28 0.05 1.45
3rd quartile 1.52 0.54 4.29 1.50 0.52 4.34
4th quartile 0.53 0.16 1.75 0.52 0.15 1.80
p-trend 0.79 0.84
Model 2
b
Table 9. Adjusted hazard ratios and 95% confidence intervals for cancer mortality and creatinine adjusted, log 
transformed urinary phthalate metabolite concentration (ug/mg), females, NHANES 1999-2006
Model 1
a
c
Assessed for 3 out of 4 series
b
Cox proportional hazard regression, adjusted for age, BMI, ratio of family income to poverty, race, smoking, education,place of birth, 
a 
Age-adjusted Cox proportional hazard regression
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